The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets. Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, we discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77. MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A. We observed increased intracellular concentrations of methylthioadenosine (MTA, the metabolite cleaved by MTAP) in cells harboring MTAP deletions. Furthermore, MTA specifically inhibited PRMT5 enzymatic activity. Administration of either MTA or a small-molecule PRMT5 inhibitor showed a modest preferential impairment of cell viability for MTAP-null cancer cell lines compared with isogenic MTAP-expressing counterparts. Together, our findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" genomic alteration.
T he gene encoding methylthioadenosine phosphorylase (MTAP) is ubiquitously expressed in normal tissues ( fig. S1 ). However, homozygous deletion of MTAP occurs frequently in cancer due to its proximity to CDKN2A, one of the most commonly deleted tumor suppressor genes ( Fig. 1A) (1-7). For example, MTAP is deleted in 40% of glioblastomas; 25% of melanomas, urothelial carcinomas, and pancreatic adenocarcinomas; and 15% of nonsmall cell lung carcinomas (NSCLC) (8) . MTAP cleaves methylthioadenosine (MTA) to generate precursor substrates for methionine and adenine salvage pathways. Synthetic lethal strategies to exploit MTAP loss with methionine starvation or by inhibiting de novo purine synthesis have been proposed; however, clinical efficacy of such approaches has not been demonstrated (9) (10) (11) .
We searched for genetic vulnerabilities associated with MTAP loss by leveraging genomescale pooled short hairpin RNA (shRNA) screening data for 216 cancer cell lines from Project Achilles (12, 13) . MTAP deletion status for each line was determined using profiles of MTAP copy number and mRNA expression from the Cancer Cell Line Encyclopedia (CCLE) (data table S1) (14) . We correlated 50,529 shRNA sensitivity profiles with MTAP deletion status across these lines and ) and the other targeted WDR77 (shWDR77 #1; P < 4 × 10 −12 ). We observed a correlation between sensitivity to these shRNAs ( Fig. 1C) , suggesting that MTAP − lines sensitive to suppression with either shRNA were generally also sensitive to suppression with the other shRNA. Cell lines with loss of CDKN2A but not MTAP were generally less sensitive to PRMT5 or WDR77 depletion than were lines with codeletion of CDKN2A and MTAP, suggesting a correlation with MTAP (but not CDKN2A) loss (Fig. 1D and fig. S2 ). To provide further support for a possible dependency on PRMT5 or WDR77 in the setting of MTAP loss, we examined additional shRNAs targeting PRMT5 and WDR77 from the screening data set. We identified a second shRNA targeting PRMT5 (shPRMT5 #2) and WDR77 (shWDR77 #2) that also demonstrated a strong correlation between impaired cell viability and MTAP loss (Fig. 1E and data table S3) . False-positive findings can occur from genomescale shRNA analyses because of "off-target" microRNA-like effects attributable to partial sequence complementarity with the 5′ end of the shRNA (known as the "seed" region) (15, 16) . To investigate this possibility, we identified shRNAs from the screening data set that shared sequence identity in the seed region with each of the four shRNAs targeting PRMT5 or WDR77. None of the shRNAs with shared seed sequence identity demonstrated a correlation between cell viability and MTAP status comparable to that observed for the shRNAs targeting PRMT5 or WDR77, arguing that the differential viability was not caused by a seed effect ( fig. S3 and tables S1 and S2). We also confirmed on-target activity of all four shRNAs against PRMT5 or WDR77 by immunoblotting of lysates from shRNA-expressing cells ( fig. S4 ).
PRMT5 and WDR77 encode critical components of the methylosome. PRMT5 forms a complex with WDR77 and catalyzes the transfer of methyl groups to arginine side chains of target proteins, including histones (involved in chromatin remodeling and gene expression) and Sm proteins (RNA-binding proteins involved in mRNA processing) (17) (18) (19) . Genetic depletion of PRMT5 has previously been reported to impair cancer cell viability by promoting G1 cell cycle arrest and apoptosis (20) (21) (22) . Interestingly, shRNAs targeting either PRMT5 or WDR77 reduced levels of both proteins (while demonstrating specific suppression of the target transcript), consistent with depletion of the methylosome complex using either shRNA ( fig. S4 ). MTAP − cells were also sensitive to shRNA-mediated depletion of CLNS1A and RIOK1, which encode two additional components of the methylosome ( Fig. 1E ) (23 Fig. 1F and fig. S2 ).
Based on these observations, we hypothesized that MTAP loss may confer enhanced sensitivity to genetic suppression of PRMT5 and WDR77. To validate this hypothesis, we examined effects of shRNAs targeting PRMT5 and WDR77 on cell viability in 275 additional cancer cell lines profiled through Project Achilles. This profiling data was generated using an expanded shRNA library with additional shRNAs not included in the initial study. Similar to findings from the initial screening data set, we observed that MTAP − lines (n = 47) were generally more sensitive to PRMT5 or WDR77 suppression than MTAP + lines (n = 228) ( Fig. 1G and data fig. S6 ).
Previous studies suggest that the activity of PRMT proteins may be inhibited by MTA (the substrate of MTAP) (24, 25) . MTA is an analog of S-adenosyl methionine (SAM), the donor substrate for PRMT-mediated methylation (26) . We hypothesized that somatic MTAP loss may lead to increased intracellular MTA concentrations, which SCIENCE sciencemag.org Mean and standard error of three to four replicates are shown. The experiment was performed two to three times for each of the four cell line pairs. **P < 0.01; *P < 0.05 by two-tailed Student's t test.
in turn confers a partial inhibition of PRMT5 activity. Together, these effects may heighten cell sensitivity to further reductions in PRMT5 activity (e.g., through genetic suppression). To test this hypothesis, we first determined whether MTAP − cells contain elevated MTA levels. We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to quantify levels of 56 metabolites (including MTA) from LU99, H647, SF-172, and SU.86.86 cells and their isogenic MTAPreconstituted counterpart lines. The abundance of most measured metabolites was not significantly altered by ectopic MTAP expression (Fig. 3A) . However, intracellular MTA abundance was reduced by a factor of 1.5 to 6, with MTAP reconstitution in each isogenic cell line pair, consistent with increased intracellular MTA in the absence of MTAP (Fig. 3, A to C) .
To determine whether MTA levels are generally higher in MTAP − cell lines compared with MTAP + lines, we quantified intracellular levels of 73 metabolites from MTAP − (n = 19) and MTAP + (n = 21) cancer cell lines from various lineages, including NSCLC, melanoma, and breast. Among profiled metabolites, the abundance of MTA was most strongly correlated with MTAP loss (Fig. 3D and data tables S5 and S6) . We observed an approximately 3.3-fold increase in median MTA levels in MTAP − lines compared with MTAP + , consistent with the hypothesis that MTAP loss leads to increased intracellular MTA (Fig. 3E) . In contrast, intracellular levels of the methyl donor SAM were not significantly different between MTAP − and MTAP + lines ( fig. S7 ). Using shRNA sensitivity data from Project Achilles, we also observed a significant correlation between MTA levels and PRMT5 dependency across profiled cell lines (Fig. 3F, fig. S7 , and data table S7).
Next, we assessed whether elevated MTA might inhibit PRMT5 activity. PRMT5 catalyzes the formation of symmetric dimethyl arginine (sDMA), whereas most other PRMTs generate asymmetric dimethyl arginine (aDMA) (17, 27, 28) . Using an antibody previously shown to recognize sDMAs generated by PRMT5 (29), we observed decreased sDMA levels in MTAP − cells compared with isogenic, MTAP-reconstituted lines (Fig. 4A ). In addition, reduced sDMA was observed in MTAPreconstituted cells exposed to exogenous MTA, consistent with inhibition of PRMT5 enzymatic activity (Fig. 4A) . Similar findings were observed with an antibody recognizing symmetric methylation of histone H4 arginine 3 (H4R3), an established substrate of PRMT5 (Fig. 4A) (30) . In contrast, we observed only modest effects of MTAP status or exogenous MTA on levels of aDMA (Fig. 4A ). This finding raised the possibility that among PRMT family members, PRMT5 may exhibit heightened sensitivity to MTA intracellular concentrations. To investigate this, we measured the ability of MTA to inhibit the catalytic function of 31 histone methyltransferases (including PRMT5 and the PRMT5/WDR77 complex), using a radioisotope filter binding assay (data (Fig. 4, C and D) . Although the results for any given cell line pair were consistent using either PRMT5 inhibitor ( fig. S9 ), the differences between each isogenic cell line pair were generally modest and more pronounced for some pairs than others (the differential sensitivity was absent altogether in SF-172). Furthermore, we did not observe significant differences in mean IC 50 values between MTAP + and MTAP − cell lines for either compound ( fig. S9 ).
The discrepancy in effect size that we observed between genetic depletion and enzymatic inhibition of PRMT5 may be caused by several factors. For example, it is possible that the reported SAM-cooperative mechanism of action of EPZ015666 limits inhibition of PRMT5 in the setting of excess MTA and reduced SAM binding (32) . Consistent with this, excess MTA is reported to increase the IC 50 of EPZ015666 by an order of magnitude in assays of PRMT5 activity (33) . In addition, we cannot exclude the possibility that a noncatalytic PRMT5 function also contributes to the dependency. In this case, therapeutic approaches to exploit this type of vulnerability may require strategies that deplete protein levels of either PRMT5 itself or the larger methylosome complex. Further work will be necessary to explore these and other mechanistic possibilities.
Collectively, our findings suggest that MTAP loss leads to increased intracellular MTA, which in turn inhibits PRMT5 activity and confers heightened susceptibility to further depletion of PRMT5 ( fig. S10) . Although PRMT5 has recently emerged as a possible therapeutic target in some cancers (26) , genetic alterations correlated with sensitivity to PRMT5 inhibition have not previously been identified. Our data suggest that many MTAP − tumors are more sensitive to depletion of the methylosome, although there is an overlapping distribution of sensitivities to PRMT5 or WDR77 suppression between MTAP − and MTAP + cell lines (Fig. 1, D , F, and G). Thus, MTAP status alone is not sufficient to distinguish cell lines that are sensitive to PRMT5 inhibition. These observations suggest the presence of other modifiers of sensitivity to methylosome depletion that function in a manner independent of MTAP status. Nevertheless, our results endorse the unexpected notion that MTAP loss confers sensitivity to PRMT5 depletion. More generally, these findings highlight the value of comprehensive functional and molecular characterization of large cancer cell line collections to promote identification of potentially targetable dependencies conferred by common genetic lesions. In vivo mapping of transcription-factor binding to the transcriptional output of the regulated gene is hindered by probabilistic promoter occupancy, the presence of multiple gene copies, and cell-to-cell variability. We demonstrate how to overcome these obstacles in the lysogeny maintenance promoter of bacteriophage lambda, P RM . We simultaneously measured the concentration of the lambda repressor CI and the number of messenger RNAs (mRNAs) from P RM in individual Escherichia coli cells, and used a theoretical model to identify the stochastic activity corresponding to different CI binding configurations. We found that switching between promoter configurations is faster than mRNA lifetime and that individual gene copies within the same cell act independently. The simultaneous quantification of transcription factor and promoter activity, followed by stochastic theoretical analysis, provides a tool that can be applied to other genetic circuits.
S equence-specific transcription factors drive the diversity of cell phenotypes in development and homeostasis (1). For each target gene, alternative transcription-factor binding configurations (by different transcription factors or by multiple copies of the same one) result in varied transcriptional outputs, in turn leading to alternative cell fates and behaviors (2, 3) . Elucidating the relations between transcriptionfactor configurations [which can number in the hundreds (4-6)] and the resulting transcriptional activity remains a challenge. Application of traditional genetic and biochemical approaches usually requires a genetically modified system or assays of purified components in vitro (7) . Ideally, however, one would like to map transcription-factor configuration to promoter activity inside the cell, with minimal perturbation to the endogenous system.
Multiple factors hinder such direct measurement. First, individual cells vary in both transcriptionfactor concentration and the resulting transcriptional activity (8, 9) ; averaging over many cells thus filters out details of the regulatory relation. Second, even within the single cell, more than one copy of the regulated gene is typically present, with each copy individually regulated (10) . Finally, even at the level of a single gene copy, multiple binding configurations are possible at a given transcription-factor concentration (11, 12) . The relative probabilities of these different configurations and the rate of switching between them will define the stochastic activity of the regulated promoter (13) .
We simultaneously measured, in individual cells, the concentration of a transcription factor and the number of mRNAs produced from the regulated gene. We also measured how the gene copy number changes through the cell cycle. We then analyzed the full single-cell data using a theoretical model, which allowed us to identify the contributions of different transcription-factor binding configurations to the stochastic activity of the promoter.
Specifically, we examined the lysogeny maintenance promoter of phage lambda, P RM . The regulation of this promoter by its own gene product, the lambda repressor (CI), is a paradigm for how alternative binding configurations drive transcriptional activity and the resulting cell fatestable lysogeny or lytic induction resulting in cell death (7) . The number of possible CI configurations is very large [>100 (4, 5) ]. Briefly, as CI concentration increases, CI dimers gradually occupy three proximal (O R1-3 ) and three distal (O L1-3 ) operator sites, leading first to activation, then repression, of P RM (Fig. 1A) . Cooperative CI binding, and looping of DNA between the O R and O L sites, play important roles in shaping the P RM (CI) regulatory curve (14) .
In a lysogen (a bacterium carrying a prophage), CI concentration is believed to be such that P RM fluctuates between the activated and repressed states (15) (Fig. 1A) , and this has been suggested to stabilize the lysogenic state against random fluctuations in CI levels (14) . However, the nature of the lysogenic "mixed state" (activated/repressed) is unknown: Are the promoter fluctuations slow
